Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

69.91 +3.71 (+5.60%)
Delayed Quote Updated: 3:48 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Exelixis (EXEL) Q3 2026 Earnings Call Transcript ↗
Cabozantinib sales grew 11% year over year as zanzalintinib advances toward FDA decisions. 
Via The Motley Fool
Topics Earnings Retirement
News headline image
What Exelixis (EXEL) Said on Its Q3 Earnings Call ↗
Exelixis (NASDAQ:EXEL) reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of... 
Via MarketBeat
Topics Earnings
Exelixis (NASDAQ:EXEL) Q3 Earnings Beat, Revenue In Line as Guidance Holds ↗
Via Chartmill
Topics Earnings
News headline image
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital ↗
Via Chartmill
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup ↗
Via Chartmill
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ↗
Via Chartmill
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗
Via Chartmill
News headline image
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock ↗
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis. 
Via MarketBeat
Topics Intellectual Property
News headline image
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy ↗
Exelixis will have to wait longer than expected to earn approval for a new drug. It's not the end of the world. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
From Exelixis, Inc.
Via Business Wire
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
Via Chartmill
News headline image
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B ↗
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle ↗
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.... 
Via MarketBeat
News headline image
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises ↗
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
News headline image
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Exelixis (EXEL) Q2 2026 Earnings Call Transcript ↗
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December. 
Via The Motley Fool
Topics Earnings
News headline image
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Exelixis Q2 Earnings Call Highlights ↗
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential... 
Via MarketBeat
Topics Earnings
News headline image
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
They are riding strong tailwinds that could lift them higher. 
Via The Motley Fool
Topics Economy
News headline image
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Sometimes, little-known stocks are worth buying. 
Via The Motley Fool
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.